Patents by Inventor Francesca ROS

Francesca ROS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-VEGF antibodies and methods of use
    Patent number: 11820816
    Abstract: The present invention relates to anti-VEGF antibodies and methods of their production and their use.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: November 21, 2023
    Assignee: Hoffman-La Roche Inc.
    Inventors: Stefan Dengl, Sebastian Fenn, Guy Georges, Joerg Moelleken, Francesca Ros, Esther Koenigsberger
  • ANTI-VEGF ANITBODIES AND METHODS OF USE
    Publication number: 20210079080
    Abstract: The present invention relates to anti-VEGF antibodies and methods of their production and their use.
    Type: Application
    Filed: June 26, 2020
    Publication date: March 18, 2021
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Sebastian Fenn, Guy Georges, Joerg Moelleken, Francesca Ros, Esther Koenigsberger
  • Method for discovery of alternative antigen specific antibody variants
    Publication number: 20200216880
    Abstract: Herein is reported a method for selecting a variant of a parental antibody variable domain encoding nucleic acid, wherein the parental antibody variable domain amino acid sequence encoded by said encoding nucleic acid has at least one developability hot spot, the method comprising the steps of (i) providing a multitude of DNA-containing samples (genomic material of antibody secreting B-cell) each including one or more antibody variable domain encoding nucleic acids; (ii) performing PCR amplification of said antibody variable domain encoding nucleic acids of (i) using consensus sequence-specific primers to obtain amplification products (wherein said consensus sequence-specific primers bind to consensus sequences that are common to a plurality of genes within the genetic loci set, thereby generating a pool of amplification products); (iii) sequencing a plurality of said amplification products obtained in step (ii) in order to determine the relative proportion of each nucleotide at each position in a sequencing
    Type: Application
    Filed: September 5, 2019
    Publication date: July 9, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guy GEORGES, Stefan KLOSTERMANN, Alain TISSOT, Francesca ROS, Alexander BUJOTZEK, Clemens WRZODEK, Frederic SCHULTZ
  • ANTI-HLA-G ANTIBODIES AND USE THEREOF
    Publication number: 20200102389
    Abstract: The present invention relates to anti-HLA-G antibodies and methods of using the same.
    Type: Application
    Filed: May 17, 2019
    Publication date: April 2, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Jens FISCHER, Meher MAJETY, Stefan DENGL, Georg TIEFENTHALER, Stefan KLOSTERMANN, Claudia KIRSTENPFAD, Esther KOENIGSBERGER, Francesca ROS
  • MONOVALENT BLOOD BRAIN BARRIER SHUTTLE MODULES
    Publication number: 20200071413
    Abstract: Herein is reported a blood brain barrier shuttle module comprising a brain effector entity, a linker and one monovalent binding entity which binds to a blood brain barrier receptor, wherein the linker couples the effector entity to the monovalent binding entity which binds to the blood brain barrier receptor wherein the monovalent binding entity does not comprise the variable domains of the anti-transferrin receptor antibody 8D3 (SEQ ID NO: 01 and SEQ ID NO: 02) or of the variant anti-transferrin receptor antibody 8D3v (SEQ ID NO: 01 and SEQ ID NO: 03).
    Type: Application
    Filed: June 28, 2019
    Publication date: March 5, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Petra RUEGER, Georg TIEFENTHALER, Ekkehard MOESSNER, Jens NIEWOEHNER, Adrian HUGENMATTER, Cuiying SHAO, Francesca ROS, Gang XU
  • Monovalent blood brain barrier shuttle modules
    Patent number: 10364292
    Abstract: Herein is reported a blood brain barrier shuttle module comprising a brain effector entity, a linker and one monovalent binding entity which binds to a blood brain barrier receptor, wherein the linker couples the effector entity to the monovalent binding entity which binds to the blood brain barrier receptor wherein the monovalent binding entity does not comprise the variable domains of the anti-transferrin receptor antibody 8D3 (SEQ ID NO: 01 and SEQ ID NO: 02) or of the variant anti-transferrin receptor antibody 8D3v (SEQ ID NO: 01 and SEQ ID NO: 03).
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: July 30, 2019
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Petra Rueger, Georg Tiefenthaler, Ekkehard Moessner, Jens Niewoehner, Adrian Hugenmatter, Cuiying Shao, Francesca Ros, Gang Xu
  • MONOVALENT BLOOD BRAIN BARRIER SHUTTLE MODULES
    Publication number: 20170051071
    Abstract: Herein is reported a blood brain barrier shuttle module comprising a brain effector entity, a linker and one monovalent binding entity which binds to a blood brain barrier receptor, wherein the linker couples the effector entity to the monovalent binding entity which binds to the blood brain barrier receptor wherein the monovalent binding entity does not comprise the variable domains of the anti-transferrin receptor antibody 8D3 (SEQ ID NO: 01 and SEQ ID NO: 02) or of the variant anti-transferrin receptor antibody 8D3v (SEQ ID NO: 01 and SEQ ID NO: 03).
    Type: Application
    Filed: July 6, 2016
    Publication date: February 23, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Petra RUEGER, Georg TIEFENTHALER, Ekkehard MOESSNER, Jens NIEWOEHNER, Adrian HUGENMATTER, Cuiying SHAO, Francesca ROS, Gang XU